ConductScience.org, home

Paper7828281

Hypersensitivity and cross-reactivity to cisplatin and analogues.

Shlebak AA and 2 others. Cancer Chemother Pharmacol, 1995. Cited by 48 papers, by iCite.

Cite this record

ConductScience Library. Hypersensitivity and cross-reactivity to cisplatin and analogues. Papers, record 7828281. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7828281

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Hypersensitivity and cross-reactivity to cisplatin and analogues.
PubMed
Journal
Cancer Chemother Pharmacol
PubMed
Year
1995
PubMed
Publication types
Case Reports, Journal Article, Review
PubMed
Citations, by iCite
48
iCite
Relative citation ratio, by iCite
1.57
iCite
Revised in PubMed
2018-11-13
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Shlebak AAA A
2Clark PIP I
3Green JAJ A

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CarboplatinMajor topic
CisplatinMajor topic
Drug HypersensitivityMajor topic
Cross Reactions
Female
Humans
Middle Aged
Ovarian Neoplasms

Source PubMed

Download CSV of topics

References22

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
13342471Positive direct antiglobulin test in a pediatric patient following high-dose cisplatin.Cancer Chemother Pharmacol1988https://conductscience.org/library/papers/3342471PubMed
23521846Phase I study of carboplatin (CBDCA) in children with cancer.Cancer Treat Rep1986https://conductscience.org/library/papers/3521846PubMed
36150229No increase in allergic reactions with intracavitary administration of cisplatin.Lancet1984https://conductscience.org/library/papers/6150229PubMed
43420679Cisplatin-induced nonimmunologic adsorption of immunoglobulin by red cells.Transfusion1988https://conductscience.org/library/papers/3420679PubMed
5387223Toxic effects of cis-dichlorodiammineplatinum(II) in man.Cancer Treat Rep1979https://conductscience.org/library/papers/387223PubMed
66134149Anaphylactic reactions to repeated intravesical instillation with cisplatin.Lancet1983https://conductscience.org/library/papers/6134149PubMed
7487238Anaphylactoid reaction to mannitol.Can Anaesth Soc J1979https://conductscience.org/library/papers/487238PubMed
891439Chemotherapy for testicular cancer: current status of the National Cancer Institute Combined Modality Trial.Cancer Treat Rep1979https://conductscience.org/library/papers/91439PubMed
96883356Phase I clinical trial of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum(IV) (CHIP).Cancer Treat Rep1983https://conductscience.org/library/papers/6883356PubMed
107201343Intravesical cisplatin for superficial bladder tumors.Cancer1982https://conductscience.org/library/papers/7201343PubMed
116761010Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/6761010PubMed
1250881Atopic hypersensitivity to cis-dichlorodiammineplatinum(II) and other platinum complexes.Cancer Res1975https://conductscience.org/library/papers/50881PubMed
137127319Phase I clinical trial and pharmacokinetics of 4'-carboxyphthalato(1,2-diaminocyclohexane)platinum(II).Cancer Res1982https://conductscience.org/library/papers/7127319PubMed
146788166Haemolytic anaemia after cisplatin treatment.Br Med J (Clin Res Ed)1981https://conductscience.org/library/papers/6788166PubMed
156204520[Allergic reaction to CDDP: report of 4 cases].Hinyokika Kiyo1984https://conductscience.org/library/papers/6204520PubMed
163546620Carboplatin and recurrent childhood brain tumors.J Clin Oncol1987https://conductscience.org/library/papers/3546620PubMed
177188625Cisplatin-induced hemolysis.N Engl J Med1980https://conductscience.org/library/papers/7188625PubMed
186697424Phase-II trial of 1,2-diaminocyclohexane (4-carboxyphthalato) platinum (II) (DACCP) in non-small cell lung cancer.Cancer Chemother Pharmacol1984https://conductscience.org/library/papers/6697424PubMed
193924402Immediate hypersensitivity to mannitol: a potential cause of apparent hypersensitivity to cisplatin.Cancer Treat Rep1985https://conductscience.org/library/papers/3924402PubMed
2087272Successful re-treatment with cis-dichlorodiammineplatinum(II) after apparent allergic reactions.Cancer Treat Rep1979https://conductscience.org/library/papers/87272PubMed

See all 22 referencesDownload CSV of references

Cited by14

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 48 citations.

PMIDTitleJournalYearIn PapersSource
42201461High-dose dexamethasone and prolonged infusion time prevent oxaliplatin-related hypersensitivity reactions in patients with metastatic colorectal cancer.Int J Clin Oncol2026https://conductscience.org/library/papers/42201461PubMed
35869676Phase II study of S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Results of the LOGIK1605/JART-1501 study.Thorac Cancer2022https://conductscience.org/library/papers/35869676PubMed
31950013A case of severe hepatotoxicity induced by cisplatin and 5-fluorouracil.Int Cancer Conf J2020https://conductscience.org/library/papers/31950013PubMed
31819881Protective effect of avenanthramides against cisplatin induced nephrotoxicity in rats.J Adv Vet Anim Res2019https://conductscience.org/library/papers/31819881PubMed
27687047Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience.Invest New Drugs2017https://conductscience.org/library/papers/27687047PubMed
24113520Nanocarriers for delivery of platinum anticancer drugs.Adv Drug Deliv Rev2013https://conductscience.org/library/papers/24113520PubMed
21475720A retrospective review of the frequency and nature of acute hypersensitivity reactions at a medium-sized infusion center: comparison to reported values and inconsistencies found in literature.J Cancer2011https://conductscience.org/library/papers/21475720PubMed
21355578Redox state-dependent interaction of HMGB1 and cisplatin-modified DNA.Biochemistry2011https://conductscience.org/library/papers/21355578PubMed
20886011Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review.Met Based Drugs2010https://conductscience.org/library/papers/20886011PubMed
19856046Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan.Int J Clin Oncol2009https://conductscience.org/library/papers/19856046PubMed
18931982[Basophil activation test as in vitro assay for cisplatin allergy].Hautarzt2008https://conductscience.org/library/papers/18931982PubMed
12888815Hypersensitivity reactions related to oxaliplatin (OHP).Br J Cancer2003https://conductscience.org/library/papers/12888815PubMed
12160138Hypersensitivity reactions to carboplatin in children.J Neurooncol2002https://conductscience.org/library/papers/12160138PubMed
11676304Prevention and management of antineoplastic-induced hypersensitivity reactions.Drug Saf2001https://conductscience.org/library/papers/11676304PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/7828281

GET https://conductscience.org/api/papers/v1/7828281/references?page=2